Appili Therapeutics Inc. (APLI.TO)
CAD 0.04
(16.67%)
CAD 0.04
(16.67%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 875.2 Thousand CAD | -88.41% |
| 2022 | 7.55 Million CAD | 54.66% |
| 2021 | 4.88 Million CAD | 415.48% |
| 2020 | 947.3 Thousand CAD | -0.34% |
| 2019 | 950.5 Thousand CAD | -10.81% |
| 2018 | 1.06 Million CAD | -2.01% |
| 2017 | 1.08 Million CAD | 152.93% |
| 2016 | 430 Thousand CAD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 850.3 Thousand CAD | -2.85% |
| 2023 Q4 | 875.2 Thousand CAD | -88.47% |
| 2023 Q2 | 7.64 Million CAD | 2.36% |
| 2023 Q1 | 7.47 Million CAD | -1.08% |
| 2023 Q3 | 7.59 Million CAD | -0.72% |
| 2023 FY | 875.2 Thousand CAD | -88.41% |
| 2022 FY | 7.55 Million CAD | 54.66% |
| 2022 Q2 | 5.31 Million CAD | 3.46% |
| 2022 Q3 | 5.33 Million CAD | 0.46% |
| 2022 Q4 | 7.55 Million CAD | 41.49% |
| 2022 Q1 | 5.13 Million CAD | 5.17% |
| 2021 Q1 | 927 Thousand CAD | -2.14% |
| 2021 FY | 4.88 Million CAD | 415.48% |
| 2021 Q4 | 4.88 Million CAD | 428.25% |
| 2021 Q3 | 924.4 Thousand CAD | -0.36% |
| 2021 Q2 | 927.7 Thousand CAD | 0.08% |
| 2020 Q4 | 947.3 Thousand CAD | -0.85% |
| 2020 Q3 | 955.4 Thousand CAD | -0.37% |
| 2020 Q1 | 949.6 Thousand CAD | -0.09% |
| 2020 FY | 947.3 Thousand CAD | -0.34% |
| 2020 Q2 | 958.9 Thousand CAD | 0.98% |
| 2019 Q2 | 943.7 Thousand CAD | 0.14% |
| 2019 Q1 | 942.4 Thousand CAD | -11.57% |
| 2019 FY | 950.5 Thousand CAD | -10.81% |
| 2019 Q4 | 950.5 Thousand CAD | 1.91% |
| 2019 Q3 | 932.7 Thousand CAD | -1.17% |
| 2018 Q4 | 1.06 Million CAD | 16.08% |
| 2018 FY | 1.06 Million CAD | -2.01% |
| 2018 Q3 | 918.1 Thousand CAD | 0.0% |
| 2018 Q1 | - CAD | -100.0% |
| 2017 Q4 | 1.08 Million CAD | 0.0% |
| 2017 FY | 1.08 Million CAD | 152.93% |
| 2016 FY | 430 Thousand CAD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Eupraxia Pharmaceuticals Inc. | - CAD | -Infinity% |
| Helix BioPharma Corp. | - CAD | -Infinity% |
| Microbix Biosystems Inc. | 6.37 Million CAD | 86.282% |
| Medicenna Therapeutics Corp. | - CAD | -Infinity% |
| Satellos Bioscience Inc. | - CAD | -Infinity% |
| Oncolytics Biotech Inc. | 290 Thousand CAD | -201.793% |
| Sernova Corp. | - CAD | -Infinity% |